Sijy J. O'Dell

The paper identifies distinct follicular helper CD4 T cell programming in HIV-positive individuals who produce broadly neutralizing antibodies, linking it to improved B cell follicle architecture and reduced suppressor cells.

This study designs a dual-epitope vaccine targeting HIV-1 Env's fusion peptide and V2 apex, showing it elicits neutralizing antibodies against both sites in rhesus macaques.

BRAVE predicts HIV-1 resistance to 33 bNAbs using a Random Forests classifier with a protein language model, outperforming existing tools in accuracy and other metrics.

This study shows that mucosal adenoviral-vectored vaccines provide durable protection against XBB.1.16 infection in nonhuman primates, outperforming intramuscular boosting in reducing virus replication in both upper and lower airways.